HOLX Business Wire 2 days ago New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
HOLX Zacks Small Cap Research 3 days ago VNRX: 3Q 2025 results reported; Revenues & EPS above our expectations; cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.
